Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy
TerminatedNCT02445235
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This observational study is designed to evaluate the reported outcomes for patients receiving topical therapy for the treatment of pain, fungal infections or skin scars. The patients will complete the Patient Reported Outcome (PRO) survey monthly and provide valuable data on the patients perception of their health status and well being while receiving therapy.
Study details
- Official title
- Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy
- Conditions
- Chronic Pain
- Fungal Infection
- Interventions
- Other: Patient Reported Outcome Survey Tool
- Sponsor
- Bracane Company
- Collaborators
- IFG Medical
- Start date
- 2015-04
- Primary completion
- 2016-01
- Sex
- All
- Age range
- from 18 Years to 85 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 3
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. An 18 to 85 years old (inclusive) female or male patient 2. Prescribed compound for the treatment of pain, wound healing or surface skin scar by their Principal Investigator 3. Any systemic disease (cardiac, renal, or hepatic) must be well controlled. 4. Has no skin lesions at the site of application of study medication except for wound under treatment 5. Able to provide informed consent Exclusion Criteria: 1. Pregnant or lactating females or women at the child bearing potential not using effective contraception. 2. Use of other topical or transdermal medication. Patients may be withdrawn for a period of 2 weeks from all topical or transdermal medications prior to study initiation. 3. Hypersensitivity to local anesthetic or other ingredients of the compounded creams to be used in a study. 4. Prior reconstruction skin surgery or skin grafts in the area of cream application preventing absorption of cream except for the treatment of surface skin scar 5. Chronic pain conditions not expected to respond to topical pain medication such as deep abdominal pain, or from conditions such as cancer, or gouty arthritis.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02445235